On Monday, the FDA approved Medtronic plc’s (NYSE:MDT) BrainSense Adaptive deep brain stimulation (aDBS) and BrainSense Electrode Identifier (EI) for patients with Parkinson’s disease. Deep brain ...
New closed-loop system self-adjusts DBS therapy to individual brain activity in real time; the largest commercial launch of brain-computer interface technology ever There is no cure for debilitating ...
For the one million people diagnosed with Parkinson's disease in the United States, Medtronic plc, a global leader in healthcare technology, proudly announces U.S. Food and Drug Administration (FDA) ...
The US Food and Drug Administration (FDA) has approved the first adaptive deep brain stimulation (aDBS) system for Parkinson’s disease (PD) that self-adjusts therapy to individual brain activity in ...
Personalized, adaptive deep brain stimulation (aDBS) is safe and effective for controlling motor symptoms over 10 months in adults with Parkinson’s disease (PD), new research showed. The ADAPT-PD ...
Medtronic Percept™ DBS therapy is the only sensing-enabled † DBS system available, allowing a physician to use data from a patient’s brain activity to personalize their treatment. Andy says Medtronic ...
Live On is a campaign that encourages patients to get to know more about neuromodulation options from Medtronic DBS. The campaign seeks to address one of the biggest challenges in Parkinson’s and ...
New closed-loop system self-adjusts DBS therapy to individual brain activity in real time; the largest commercial launch of brain-computer interface technology ever GALWAY, Ireland, Feb. 24, 2025 ...
Please provide your email address to receive an email when new articles are posted on . The adaptive deep brain stimulation technology is the first of its kind to address symptoms of Parkinson’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results